The cellular and molecular mechanisms underlying neurodevelopmental conditions such as autism spectrum disorders have been studied intensively for decades. The ability to generate patient-specific induced pluripotent stem cells (iPSCs) now offers a novel strategy for modelling human diseases. Recent studies have reported the derivation of iPSCs from patients with neurological disorders. The key challenge remains the demonstration of disease-related phenotypes and the ability to model the disease. Here we report a case study with signs of neurodevelopmental disorders (NDDs) harbouring chromosomal rearrangements that were sequenced using long-insert DNA paired-end tag (DNA-PET) sequencing approach. We identified the disruption of a specific gene, GTDC1. By deriving iPSCs from this patient and differentiating them into neural progenitor cells (NPCs) and neurons we dissected the disease process at the cellular level and observed defects in both NPCs and neuronal cells. We also showed that disruption of GTDC1 expression in wild type human NPCs and neurons showed a similar phenotype as patient's iPSCs. Finally, we utilized a zebrafish model to demonstrate a role for GTDC1 in the development of the central nervous system. Our findings highlight the importance of combining sequencing technologies with the iPSC technology for NDDs modelling that could be applied for personalized medicine. † equal contribution.
Introduction
Chromosomal rearrangements have broad functional consequences that largely depend on the size of the affected region, copy number alteration and the affected genes within the rearrangement. Apparently balanced chromosomal anomalies (ABCR) may be detected during pre-or postnatal investigation, and can provide predictive information for congenital or neurodevelopmental defects. The frequency of ABCR is approximately 1 in every 2000 live births, and about 15% of neurodevelopmental disorder (NDD)-associated phenotypes are attributed to cytogenetically visible abnormalities (1) (2) (3) (4) (5) (6) . The majority of NDD cases (60-80%) have unknown genetic causes, and are predominantly characterized by intellectual disability or often associated with multiple congenital anomalies (6) . Balanced and unbalanced structural genomic rearrangements lead to variations in gene expression and dosage that are important contributors to the phenotypic complexity associated with these conditions.
We have established a next-generation sequencing pipeline, referred to as a DNA paired-end tag (DNA-PET) sequencing in which we sequence the ends of large-insert sizes of 7 to 11 kb genomic DNA fragments, resulting in high physical coverage to identify large genomic structural variations at a high resolution (7) (8) (9) . In a previous study, we implemented this technique to screen the whole genome of multiple patients with developmental delay, intellectual disabilities and speech disorders and identified a set of candidate genes involved in NDDs (10, 11) . Moreover, for one of the candidate genes, MED13L, we have demonstrated its haploinsufficiency affecting the patient's phenotype by using the zebrafish model (10) .
A breakthrough was made in 2006 when Yamanaka's group demonstrated that a set of four transcription factors: Pou5f1 (also known as Oct3/4, Octamer3/4), Sox2 (SRY box containing gene 2), Klf4 (Kruppel-like factor 4) and c-Myc, referred to as OSKM, were able to convert differentiated cells into pluripotent cells presenting the same characteristics as embryonic stem cells (ESCs) (12) . This discovery allows the generation of patient-specific induced pluripotent stem cells (iPSCs) that can be differentiated into any cell type of the human body and used for cell replacement therapy, disease modelling, and drug or toxicology screening studies. iPSCs have been generated from patients with neurological disorders, including the Rett syndrome and Parkinson's disease (13) (14) (15) (16) (17) (18) . By directing differentiation of these iPSCs into disease-relevant cell types in vivo defects were mimicked in vitro.
In this study, we combined DNA-PET next-generation sequencing (NGS) sequencing with the iPSC technology and the use of a zebrafish model to identify and characterize candidate genes involved in the neurodevelopmental disorder of a patient harbouring chromosomal abnormalities. By DNA-PET sequencing of a complete trio (both parents and affected child) we identified a single de novo rearrangement disrupting the glycosyltransferase like domain containing 1 gene: GTDC1. To determine the cellular consequences of GTDC1 disruption, we generated iPSCs. The differentiation of these iPSCs into neural progenitor cells (NPCs) and neurons revealed defects in proliferation, maturation and glycosylation status. Moreover, silencing of GTDC1 in wild-type human NPCs and their differentiation into neurons showed consistency with the patient's cell phenotype. Finally, disruption of gtdc1 in the zebrafish model highlighted defects in brain development that could potentially explain the patient's phenotype.
This work provides a basis for a personalized medicine approach that combines sequencing technologies with disease modelling using the iPSC technology and animal models.
Results

Identification of GTDC1 disruption by DNA-PET sequencing
We investigated a patient afftected by global developmental delay, speech delay and language impairments, and harbouring a de novo t(2;8) translocation based on karyotype analysis (Supplementary Material, Fig. S1A ). To identify de novo genetic variations associated with cognitive impairments, paired-end tag sequencing of the genomes was performed on the index patient and both parents (Fig. 1A) . We generated an average of 61 million paired-end tag (PETs) reads for each library (Supplementary Material, Table S1 ). The majority of PETs mapped accordingly to the reference genome and were referred as concordant PETs (cPETs). cPETs also provide information regarding copy number variation based on the number of sequencing reads (8, 11) . The remaining PETs were referred as discordantly mapped PETs (dPETs). dPETs that form clusters by connecting repeatedly the same genomic regions allow the identification of structural variants (SVs) for which the cell specificity is determined by the cluster size (Supplementary Material, Table S2 ). Approximately 96% of the predicted SV calls generated for each library were shared with normal individuals published in the Database of Genomic Variants (DGV), 1000 Genome Project SVs release set, and previous paired-end sequencing studies in healthy individuals (19, 20) , which were included as part of the SVs filtering pipeline. Through these analyses, we obtained 635 patient-specific SVs, of which 616 were detected in one or both parents, indicating that these were germline variants (Fig. 1B , Supplementary Material, Table S1 ). The percentage of paternal and maternal inheritance rates were 46.1 and 52.5%, respectively. Upon exclusion of germline SVs and common SVs, four de novo SVs specific to the proband were identified (Fig. 1B) ; two of which correspond to the balanced translocation t(2;8) observed in the karyotype (Supplementary Material, Table S2 ). Sequence validation of the PCR-amplified breakpoint junction revealed the precise translocation breakpoints at position chr2:144,606,846 and chr8:23,007,141-23,007,144 with a loss of 3 bp in chromosome 8 and a microhomology of 5 bp between the flanking regions (Supplementary Materials, Fig. S2 , Table S3 ). Given the precise breakpoints coordinates, the karyotype was then revised from 46,XY,t(2;8)(q23;p21) to 46,XY,t(2;8)(q22;p21). The chromosome 8 breakpoint does not disrupt any annotated gene, while the chromosome 2 breakpoint is located in intron 5 of GTDC1, a gene that encodes glycosyltransferase domain-like containing protein 1. Based on secondary CNVs screening in developmental delay (DD) cases by Cooper et al. (21) and the DECIPHER consortium dataset, we found 16 deletions and 5 duplications overlapping with GTDC1 (Fig. 1C) , and no variant was found in the Database of Genomic Variants and control datasets. To generate a comprehensive genome-wide view of patient CD6 SVs, we integrated aCGH data, cPET-based copy number data, and DNA-PET SVs into a Circos plot, and did not observe large scale SVs apart from the t(2;8) translocation (Fig. 1D) . We found reduced level of GTDC1 mRNA and protein (45% reduction) compared to two control patients ( Fig. 1E and F) . The differential expression observed between amplicons at exon 5-6 and 7-8 may be due to the primers' efficiency and/or to a regulation of the translocated exons via a potential cryptic regulatory region at chromosome 8. Moreover, quantitative RT-PCR analysis showed that GTDC1 is ubiquitously expressed in human fetal tissues, with high expression observed in the fetal brain and cerebellum (Fig. 1G) . 
Patient CD6 iPSCs show defects in neural progenitor cell proliferation
To show that GTDC1 might be causative of the disease, we generated iPSCs (22) from the patient's fibroblasts to dissect cellular and functional defects specific to the patient's cells. We generated multiple iPSC lines that were compared to two control iPSCs lines derived from fibroblast of two healthy individuals. We first characterized the iPSCs and showed that two independent patient-iPSCs cell lines (clone #5 and #15) expressed pluripotency markers at levels comparable to control iPSCs, as shown by immunocytochemistry for OCT4, NANOG, SSEA4, and TRA-160 ( Fig. 2A) and quantitative RT-PCR for NANOG, OCT4, SOX2, and KLF4 (Supplementary Material, Fig. S3A ). We analysed the expression level of GTDC1 protein in reprogrammed cells and observed a decrease of 58% compared to control cells indicating that reprogramming does not affect the reduced level of GTDC1 protein of the patient's cells (Fig. 2B ). These cells can be induced to differentiate by formation of embryoid bodies when plated in suspension and express markers of the three germ layers: ectoderm, mesoderm and endoderm as shown by immunostainnings and PCR analysis (Supplementary Material, Fig. S3B ). These data confirmed the successful reprogramming of patient's fibroblasts into iPSCs and their pluripotency. We analysed the karyotype of these iPSCs and observed the conservation of the t(2;8) translocation after reprogramming (Supplementary Material, Fig. S1B ).
As patient CD6 harbours neurological defects, we differentiated patient CD6-iPSCs into neural progenitor cells (NPCs), which we refer as CD6-NPCs, by the synergistic inhibition of glycogen synthase kinase 3 b (GSK3b), transforming growth factor b (TGF-b), and Notch signalling pathways by small molecules (23) . After one week of in vitro differentiation, CD6-NPCs were positive for neural stem cell markers SOX2, PAX6, NESTIN, BLBP and SOX1 in comparable levels to human ESCs differentiated into NPCs and NPCs generated from control patients' iPSCs ( Fig. 2C and D) , and no longer expressed the pluripotency markers NANOG and OCT4 (Fig. 2D) . To investigate the proliferative capacity of these NPCs, we performed EdU-incorporationbased cell cycle analysis and observed a significant decrease of proliferation rate in CD6-NPCs (reduction of 11.8% 6 0.56) (Fig. 2E) . We also characterized the transcriptome of CD6-NPCs by microarray analysis and identified significant differences between control and CD6 patients' cells. Indeed, 1448 genes were found to be down-regulated in CD6-NPCs compared to ControlNPCs including GTDC1 and 868 genes up-regulated (Supplementary Material, Table S4 ). Interestingly, the GO analysis of downregulated genes in CD6-NPCs revealed enrichment in cell cycle regulation terms, in conjunction with the slower proliferation rate we observed in these cells (Fig. 2F) . The GO analysis was less significant in terms of p-value for upregulated genes, nevertheless the outcome pointed to dysregulations in protein localization and vesicular transport terms (Fig. 2F) . GTDC1 encodes an enzyme involved in protein glycosylation, and glycosylation has been shown to play a crucial role in neural functions (24, 25) . We first confirmed the downregulation of GTDC1 transcript expression in CD6-NPCs (Fig. 2G ) and then assessed the expression and localization of ICAM-1, which has been described as a glycosylation biomarker as it is a membrane protein that is degraded and rendered unstable upon hypoglycosylation (26) . We observed very different patterns of ICAM-1 protein expression in control-NPCs versus CD6-NPCs; clear staining localized in cells' membrane for control cells and a dotted staining for CD6-NPCs that looks similar to protein aggregates (Fig. 2H) . We also checked the ICAM-1 expression at the mRNA level by qRT-PCR and showed a decrease in patient's CD6-NPCs compared to control NPCs (Fig. 2H ).
Patient CD6 iPSCs show defects in neuronal maturation and neurogenesis
The proliferative characteristics of NPCs are very important for proper differentiation into neurons (27) . Therefore, we differentiated CD6-NPCs into neurons (Fig. 3A) . We used a neuronal differentiation assay that mostly leads to the generation of GABAergic neurons as these neurons have been shown to be impaired in many neurodevelopmental disorders (28) (Fig. 3A and Supplementary Material, Fig. S4 ). We then checked the expression level of GTDC1 mRNA in these neurons to confirm its downregulation in patient's neurons (Fig. 3B) . We further characterized the neurons and did not observe any remarkable differences in neuronal differentiation efficiency based upon expression the TuJ1 marker. However, when we investigated the maturation of TuJ1 positive neurons into MAP2 positive neurons, we observed lower maturation efficiency for neurons derived from CD6-NPCs when compared to Control-NPCs (reduction of 24.2 6 6.37%) (Fig. 3C ). Decrease in neuronal soma size has been described previously for neurons derived from Rett Syndrome iPSCs and suggest a sign for defect in transcriptional and translational machinery of the cells (29) . We therefore analysed the soma size of our neuronal population and observed a slight decrease of CD6-neurons soma size compared to Control-neurons (reduction of 49.43% 6 0.86) (Fig. 3D,  Supplementary Material, Fig. S5 ). An important function for neurons is their ability to fire action potentials, which allows for proper signalling in the nervous system. The axon caliber has been shown to be important for firing frequency (30) and we observed a difference of the axon caliber between control and patient cells. Indeed, we measured a reduction of 40.04% 6 2.03 of the axon thickness in CD6-Neurons compared to control neurons (Fig. 3E) . Neuronal communications are the key for proper brain development and functionality. This is mainly controlled by synapses that arise in neurites. Therefore, it is important to have a sufficient number of neurites for proper transmission of the neuronal information. The average number of neurites in neurons derived from non-altered neurons is between 4 and 6 (31, 32) . Based on this, we focused on neurites present in neurons we have generated and observed an important difference in CD6-neurons neurites density compared to Control-neurons when plated at low density, with an average of 5.17 6 0.9 neurites for Control-neurons and 2.17 6 0.39 for CD6-neurons (Fig. 3F ). These results show that CD6 patient's cells harbour defects in neuronal maturation and suggest a possible disruption in neuronal signalling and connectivity due to their reduced soma size, smaller caliber and lower number of neurites per cell body.
In parallel to the functional analysis, we characterized Control-and CD6-neurons at the transcriptional level. We highlighted the presence of 275 genes expressed at higher levels in CD6-neurons and 231 at lower levels. GO analysis showed enrichment for neurological terms (Fig. 3G , Supplementary Material, Table S4 ). Downregulated genes in CD6 neurons showed enrichment in mechanisms involving glycosylation processes including collagen, glycosaminoglycan and polysaccharide binding, which corroborates with GTDC1 function (Fig. 3G) . Next, we asked whether the genes with altered expression in CD6-NPCs and neurons have been previously implicated in patients with ID or Table S5 ).
Knock-down of GTDC1 in human ESCs induces similar phenotypes as CD6 patient's cells
To determine if the disruption of GTDC1 is causative of the patient's neurodevelopmental disorder, we knocked-down its expression by stable RNA interference using NPCs derived from H1 human embryonic stem cells (hESCs). Indeed, as the patient is affected by a translocation and that current technologies do not allow for the rescue or for mimicking this type of important chromosomal rearrangements, we opted for this strategy in order to further investigate the effect of GTDC1 disruption. We selected two control non-targeting shRNA and two shRNA sequences with a knock-down efficiency of approximately 50% of the mRNA level ( Fig. 4A ) and 60% of the protein level compared to control cells (Fig. 4A ). We then characterized these shGTDC1-NPCs using a similar profiling pipeline as for CD6-NPCs. We show here the average data obtained with both controls. SOX2 and NESTIN immunocytochemistry showed similar morphology for hESCs-and shGTDC1-NPCs (Fig. 4B ). We observed a decrease in proliferation of shGTDC1-NPCs (reduction of 10.56% 6 2.20) (Fig. 4C ) comparable to CD6-NPCs. Transcriptomic analysis showed a decrease in several cell cycle genes in shGTDC1-NPCs including CyclinE1 (CCNE1) which plays an important role in multiple phases of the cell cycle (Fig. 4D) . Furthermore, we checked the ICAM-1 expression at the protein level by immunocytochemistry ( Fig. 4E ) and found a mislocalization as in CD6-NPCs similar to CD6-patient's NPCs, and at mRNA level by qRT-PCR and found that overall mRNA expression of ICAM-1 is reduced in shGTDC1-NPCs compared to control cells. We further differentiated shGTDC1-NPCs into neurons and observed a decrease (i) in soma size with a reduction of 26.89% 6 10 ( Fig.  4F ), (ii) in neuronal maturation assessed by TuJ1þ versus MAP2þ neurons with 11.75% 6 1.12 less MAP2þ neurons in shGTDC1 condition (Fig. 4G ) and (iii) in neurites density with 5.66 6 1.07 neurites per cell body for shControl and 2.67 6 0.69 for shGTDC1 neurons (Fig. 4H ). These similarities in the proliferative capacity and neuronal phenotypes between patient's derived cells and shGTDC1 cells suggest that GTDC1 plays a role in the patient CD6 disease aetiology. It is important to note that the effects observed using shRNA experiments are less pronounced than those obtained with patient's iPSCs. This could reflect an effect of the genetic background of the patient. We finally compared CD6 #5 and CD6 #15-NPCs and Neurons with shGTDC1 #1 and #3-NPCs and Neurons at the genome wide level. Among the differentially expressed genes in CD6-iPSCs versus Control-iPSCs and shGTDC1 versus shScrambled, we found 49 and 61 genes that were shared between CD6 cells and shGTDC1 cells at NPCs and neurons, respectively (Fig. 4I , Supplementary Material, Table S6 ). Among the commonly regulated genes, some have been shown to be important for neural development including SNAP25, DPYSL4, SNAI2, FRMD6. We further confirmed the differential expression of these genes of interests by qRT-PCR (Supplementary Material, Fig. S6 ).
Knock-down of gtdc1 induces impaired development of the central nervous system in zebrafish
The zebrafish has become a well-established model organism, making important contributions to the identification and characterization of genes and pathways involved in development and organ function (34) . Additionally, it has become a valuable resource for identifying genes involved in human diseases (34, 35) . Moreover, it has recently been shown that 70% of protein-coding human genes are related to genes found in the zebrafish, and 84% of genes known to be associated with human diseases have a zebrafish counterpart (36) . We therefore used this model to further investigate the role of GTDC1 in vivo. For this, we injected morpholino (MO) antisense oligonucleotide targeting gtdc1 orthologue in zebrafish embryos to mimic GTDC1 deficiency. We achieved $40% knockdown efficiency as measured by qRT-PCR (Fig. 5A) . Loss of gtdc1 expression in the zebrafish did not result in embryonic lethality, as demonstrated by 80-90% survival rate in each injection batch (Fig. 5B) . Suppression of gtdc1 by injection of 4 and 8 ng of gtdc1-MO into 1-cell stage embryo resulted in developmental defects including microcephalic head, microphtalmia, and curved body axis at 70.9% (Fig. 5C ). The co-injection of 200 pg of human GTDC1 mRNA was sufficient to rescue the phenotype (Fig. 5C ). Guided by the cognitive defects in our patient, we further performed phenotypic analysis in these morphant embryos. To examine the affected brain regions, we performed in situ hybridization with fgfr3 that is expressed in the midbrain, hindbrain, and telencephalon of the zebrafish (37, 38) . We observed no differences between wild-type and morphant embryos (Fig. 5D) . We further checked the expression of islet1 that is expressed in the forebrain, hypothalamus and retinal ganglion cells (RGCs) of the zebrafish (39) . Interestingly, we observed reduced expression of islet1 in the forebrain and hypothalamic region of gtdc1 morphants at 48 hpf compared to the control embryos (Fig. 5D) . Moreover, islet1 expression was undetectable in the RGCs of gtdc1 MO embryos at 48 hpf (Fig. 5D ). These observed phenotypes can be partially rescued by co-injection of morpholino antisense and human full length GTDC1 mRNA (Fig. 5D ). To assess whether GTDC1 disruption affects the neuronal distribution in the CNS we injected gtdc1 MO into the HuC:GFP transgenic zebrafish line, in which cells that start to develop as neurons initiate the expression of the Green Fluorescent Protein (GFP) driven by the HuC promoter (40, 41) . HuC has been shown to be first expressed in the neuronal precursor cells of the neural plate and is used as an early neuronal marker (40) . We observed an excess of neurons in the dorsal median midbrain in gtdc1 MO embryos, whereas wild-type and rescued embryos showed relatively similar distribution in the forebrain, mid-hindbrain boundaries and spinal cord (Fig. 5D) . These results suggest that gtdc1 knockdown impaired development of the CNS in zebrafish embryos. Moreover, the high number of GFP positive cells observed after gtdc1 MO can be correlated with the maturation defect observed in iPSCs-and GTDC1 knocked-down ESCs-derived neurons ( Figs 3C and 4G) .
Discussion
This study demonstrates the value of a genome-wide sequencing strategy in investigation of patients with ABCR, in combination with iPSC technology for validation of candidate disease genes. Recent studies have described the feasibility to detect ABCR in NDD patients associated with chromosomal anomalies by using various sequencing technologies (42-48). These technologies include (i) a shotgun sequencing approach using flow-sorted derivative chromosomes (42), (ii) custom jumping libraries coupled with the targeted breakpoint capture (47) , which are limited to the chromosomal breakpoint regions, (iii) standard paired-end sequencing or large-insert jumping libraries of 3-4 kb (43, 46, 47) , and (iv) mate-pair sequencing of 2-3 kb insert sizes (44, 45) . These approaches performed well in terms of precision of the ABCR breakpoint detection and characterization of germline chromothripsis rearrangements (43) (44) (45) . However, these studies did not clearly describe the presence of additional structural variants beyond the actual chromosomal breakpoints. Here, we implemented an efficient DNA-PET sequencing strategy using large insert sizes (between 7 and 11 kb) which has already been successfully applied to various cancer genomes to characterize specific SVs patterns (7, 8, (49) (50) (51) and also in NDDs (10, 11) . We applied this technology to analyse the whole genome of a single patient with NDDs harbouring chromosomal anomalies. This is important because, while breakpoints are disrupting potentially interesting genes, the correlation between affected genes and disease aetiology is still a challenge for rare disorders. We took advantage of the availability of the patient's parental DNA to perform a trio analysis, and identified only one de novo SV that disrupted a single gene GTDC1. To evaluate GTDC1 in relation to the patient's disease and its involvement in NDDs in general, we performed functional characterization of this gene by using an iPSC-based modelling approach coupled with RNA interference on wild-type human ESCs. These experiments revealed aberrations in both the NPCs and neuronal cells derived from these cells. We first observed defects in the proliferation rate of NPCs derived from the patient's iPSCsand knocked-down ESCs. The ability to proliferate is a defining property of neural stem cells as it allows them to differentiate efficiently into different cell types including neurons and glial cells. Disruption of NPCs proliferation efficiency has been observed in brain sections of patients with schizophrenia as well as those with Huntington's disease (52, 53) . In the case of this patient, we show that the decrease in proliferation of NPCs seems to affect neuronal maturation. Interestingly, we observed the same results in wild-type human NPCs generated from hESCs and knocked-down for GTDC1. These data suggest that GTDC1 may be involved in the patient CD6 neurodevelopmental phenotype. We observed common characteristics between our patient's neurons and neurons derived from other NDDs modelling studies including the reduction of the soma size (29) , and decrease in neurite numbers per cell body (16, 54) . Again, these observations were also seen in neurons knockeddown for GTDC1, implying the possible causative effect of this gene in the patient's phenotype. In addition to these data, we also observed a decrease in the axonal thickness of the patient's neurons that might affect their firing frequencies (30) . We opted here for the RNA interference strategy to try to mimic GTDC1 disruption. However, we are conscious that the genetic background must be taken into consideration when studying diseases. Moreover, the analysis of microarray data from the patient's and shGTDC1 cells showed a limited overlap in NPCs and neurons. This can be due to the fact that knocking-down GTDC1 may not be sufficient to mimic its disruption in the patient's cells. An analysis of the molecular consequences of the translocation on GTDC1 would help answer this question. One possible outcome of GTDC1 disruption could be the generation of a dominant negative form which could explain why the phenotype observed in knocked-down hESCs is less severe than the phenotype of the patient's iPSCs and/or the small overlap between both cell types. Therefore, we went one step further by studying the role of GTDC1 in vivo using the zebrafish model that has been shown to be a valuable model for characterizing the function of multiple genes involved in human diseases. It was interesting to observe defects in the development of CNS in the zebrafish that corroborates with the patient's phenotype and strengthens the data we obtained using the iPSC technology. It is now possible to generate cell lines harbouring karyotype abnormalities using the CRISP/Cas9 system (55), it would be interesting to apply this strategy to study our patient's phenotype.
Although GTDC1 function is not well characterized, it is known to be involved in glycosylation processes. We observed a mislocalization of ICAM-1 which has been described as a hypoglycosylation marker. Adhesion molecules have been shown to be particularly important in the neural stem cell niche environment and also for stem cell based therapy for neural disorders (28) . Together, these data show a significant impact of a GTDC1 disruption on the neurogenesis process at the cellular level. Mutations in glycosyltransferases have been associated with congenital disorders of glycosylation (MIM 212067), which is caused by defects in the synthesis of glycans. The clinical spectrum of CDG identified so far is variable from mild to severe metabolic defects involving a wide range of neurodevelopmental abnormalities (56-59). While we identified a GTDC1 disruption in one patient, copy number gains and losses overlapping GTDC1 have been described in previous case studies (21, 60) . The case reported by Mulatinho et al. (2012) concerns a patient exhibiting an approximately 6 Mb deletion of chromosome 2 that affect multiple genes including HNMT, SPOPL, NXPH2, LOC64702, LRP1B, KYNU, ARHGAP15 and GTDC1. Our patient does not show any disphormic features in contrary to this patient that exhibits multiple malformations (deep-set eyes, protruding tongue, small teeth etc. . .). Interestingly, both patients present similar features in terms of intellectual disability/mental retardation/developmental delay and autism spectrum disorder. These data reinforce the potential role of GTDC1 as an important gene involved in neurodevelopmental disorders. Generating iPSCs from this patient and others will provide better understanding in comparison to our patient and further confirm the role of GTDC1 in NDDs. The DNA-PET analysis of our patient's genome allowed the identification of an intronic duplication for SETD2 inherited from the mother and an intronic deletion for CNOT4 inherited from the father. For all SVs that coincide within intronic region of genes we assessed the probability score of functional regulatory regions using RegulomeDB and ENCODE data in the UCSC genome browser. For both genes the results were not significant indicating that the disruptions observed certainly do not affect their expression or protein conformation. Moreover, the sole knockdown of GTDC1 in hESCs induces similar phenotypes as hiPSCs derived from our patient suggesting the important role of GTDC1 in the patient's phenotype.
We showed using the iPSC technology in conjunction with genomic screening of one patient that GTDC1 disruption contributes to the pathogenesis of NDDs. As genome sequencing becomes a routine diagnostic procedure, genomic screening coupled with deriving patient's iPSC will provide a deeper understanding of the underlying genetic causes of rare diseases.
Materials and Methods
Patient
DNA samples were obtained from peripheral blood lymphocytes and cultured skin fibroblasts at the Centre Hospitalier Regionale d'Orleans in Orleans, France. Samples and information were collected after consent of each individual and their legal guardian when necessary. Consents were obtained in accordance with local institutional review board approved protocols by National University of Singapore in Singapore, and Centre Hospitalier Regional in Orleans.
The patient is the fifth child from a second marriage of a healthy mother and father. During pregnancy, amniocentesis was done for advanced maternal age and revealed a de novo translocation 46,XY,t(2;8)(q23;q21). Ultrasound examination was normal, and the pregnancy continued to term. The baby was born at term with Apgar score 10-10. At the age of two years, he presented with global DD (Developmental Delay) without dysmorphic features or growth delay. He had excessive salivation and deep tendon reflexes. He initially walked on tiptoe, but subsequently reverted to normal by six years of age. At the age of four years, he had a global mental deficiency, speech delay and language impairment. DNA of the patient, and both biological parents were used for DNA-PET analysis. Mother and father are referred to as CD15 and CD16, respectively.
Cytogenetic and FISH analysis
Karyotypes were determined from G-banding analysis using standard protocol according to the ISCN nomenclature. Metaphase chromosomes were prepared from cultured skin fibroblast cells. Fluorescence in situ hybridization (FISH) was performed on metaphase chromosomes using BAC and fosmid probes (BACPAC Resources, CHORI), selected based on human reference genome NCBI Build 36. Probes were labelled in the presence of biotin-16-dUTP or digoxigenin-11-dUTP (Roche) using the Nick translation system (Enzo). Probes were resuspended at a concentration of 5 ng/ml in hybridization buffer (2xSSC, 10% Dextran Sulphate, 1Â PBS, 50% Formamide) in the presence of 1 mg/ml Cot1 DNA (Life Technologies). Prior to hybridization, metaphase slides were pre-treated with 0.01% pepsin for 5 min at 37 C followed by 1Â PBS wash (5 min), 1% formaldehyde 10 min treatment, 1ÂPBS wash (5 min) and dehydration through ethanol series (70, 80 and 100%). Probes and slides were co-denatured for 5 min at 75 C and hybridized overnight at 37 C. After post-hybridization washes, the slides were revealed with avidin-conjugated fluorescein isothiocyanate (FITC) (Vector Laboratories, CA) or anti-Digoxigenin-Rhodamine (Roche). Slides were mounted with VectaShield (Vector Laboratories, CA) and observed under an epifluorescence microscope (Nikon). Image analysis was performed using the ISIS Metasystems.
Genomic DNA preparation
Genomic DNA from patient's fibroblasts was extracted by Qiagen Blood and Cell Culture DNA Kits (Qiagen), according to manufacturer's instruction. Fibroblast cell lines were maintained to a minimum number of passages prior to DNA extraction. Quality and quantity of the extracted DNA were measured using NanoDrop 1000 Spectrophotometer and agarose gel electrophoresis.
Array comparative genomic hybridization
Array comparative genomic hybridization (aCGH) was performed using the SurePrint G3 Human 2 x 400k aCGH Microarray (Agilent Technologies Inc. Santa Clara). The microarray slides were scanned on an Agilent Microarray Scanner. The data were processed by Genomic Workbench software, standard edition 5.0.14 (Agilent). We used the Aberration Detection Method (ADM-2) algorithm to identify DNA copy number variations (CNV). The ADM-2 algorithm identifies all aberrant intervals in a given sample with consistently high or low log ratio based on the statistical score. We applied a filtering option of minimum three probes in the region and a centralization threshold of 6. We used NCBI Build 36 as a reference genome. For smaller CNVs that were identified by DNA-PET, we compared them with the aCGH raw data and interpreted the copy number changes by looking at the individual probes ratio, using a cutoff of 0.1 (<0.1 indicated deletion, >0.1 indicated duplication).
DNA-PET library construction
DNA-PET libraries were constructed for each sample according to Hillmer et al. (8) . Briefly, genomic DNA was hydrosheared to 7-10 kb DNA fragments. Long Mate Paired (LMP) cap adaptors were ligated to the hydrosheared and end repaired DNA fragments. The cap adaptor-ligated DNA fragments were separated by agarose gel electrophoresis, recovered using the QIAEXII Gel Extraction Kit (QIAGEN) and circularized with a biotinylated adaptor that connects the cap adaptors at both ends of the DNA fragments. Missing 5' phosphate groups of cap adaptors created a nick on each strand after circularization of the DNA. Both nicks were translated outwards by >50 bp into the circularized genomic DNA fragment by DNA polymerase I (NEB). The nicktranslated constructs were then digested with T7 exonuclease and S1 nuclease (NEB), to release paired-end tag (PETs) library constructs. These constructs were ligated with SOLiD sequencing adaptors P1 and P2 (Life Technologies), and amplified using 2Â HF Phusion Master Mix (Finnzymes OY) for sequencing. High throughput sequencing of the 50 bp libraries was performed on SOLiD sequencers (v3plus and v4, respectively) according to the manufacturer's recommendation (Life Technologies). Sequence tags were mapped to the human reference sequence (NCBI Build 36) and paired using SOLiD System Analysis Pipeline Tool Bioscope, allowing up to 12 colour code mismatches per 50 bp tag and up to 4 colour code mismatches per 35 bp tag.
DNA-PET data curation
The majority of the PET sequences mapped accordingly to the reference genome (concordant PETs or cPETs) with an expected mapping orientation (5' tag to 3' tag) and expected mapping distance (according to the selected fragment size). The distribution of cPET in the genome was used to retrieve copy number information. The remaining portion of the PETs mapped discordantly to the reference genome (discordant PET or dPETs), classified as those with incorrect paired-tag orientation and incorrect genomic distances. These dPETs provided information to search for genomic rearrangements; with specific criteria for different types of SVs according to PET mapping orientation and genomic region. The overlapping dPETs representing similar SVs were clustered together as dPET clusters and counted as the cluster size, according to the procedure as described in Hillmer et al. (8) with refined data curation as described in Ng et al.
.
Filtering of normal structural variations (SVs)
Comparison of clusters across different genomes was performed as described by Ng et al. (7) . We included DNA-PET data of 23 normal individuals (25 DNA-PET data sets) and the pilot release set of 1000 Genome Project from Mills et al. (61) in the cross-genome comparison, and identified SVs that were present in the normal libraries. In addition, we used the breakpoint locations to compare the identified SVs with published SVs based on paired-end sequencing studies of 18 additional normal individuals (19, 20) and Database of Genomic Variants (See Web Resources). The fraction of predicted SVs which overlapped with a published SV was calculated by the percentage of overlap relative to the larger event. Thus, we categorized SVs that overlapped by 80% or more with those identified by these studies as "normal" SVs. Thus, SVs classified as "normal" have been excluded to identify rearrangements which underlie the diseases.
For the identification of matching SVs within the parent offspring trio in patient CD6, cross-genome comparison was generated for the trio, including normal individual datasets. Filtering of sequencing artefacts was performed according to DNA-PET data curations. SVs were classified into; (i) maternal-identical SVs, x, shared between mother and offspring, (ii) paternalidentical SVs, y, shared between father and offspring, (iii) identical germline SVs, z, shared within the trio and presumably found in the normal population, (iv) non-identical SVs, de novo SVs exclusively found in the offspring. The rates for maternal and paternal inheritance are calculated from the percentage between maternal/paternal-identical SVs compared to the total number of maternal/paternal SVs. Normal SVs were further filtered in non-identical SVs, and resulted in four de novo SVs specific to the patient CD6.
Functional analysis of regulatory regions
The hg18 coordinates of genomic regions from each patient's SVs list were converted to hg19 in LiftOver from UCSC genome browser. SVs that coincide within the intronic region of genes or non-coding regions were assessed for the probability score of functional regulatory regions in RegulomeDB and ENCODE data in UCSC genome browser. 
Validations of the expected breakpoints by PCR
Western blot
Protein extracts from patient's skin fibroblasts were prepared using RIPA lysis buffer (Sigma) supplemented with protease inhibitors (Roche). Western blot analysis was performed using an antibody against GTDC1 (1/100, Atlas antibodies, HPA036694) and Actin (1/2000, Millipore, CBL171). Proteins were incubated simultaneously with both antibodies.
iPSCs generation
Human fibroblasts were reprogrammed to iPS cells by retroviral transduction of transcription factors following established protocols (22) . For virus production, 293GP2 cells were plated at 80% confluence per 100-mm dish and transfected with 8 lg of each retroviral vectors (OCT4, KLF4, c-MYC and the mouse Sox factor) plus 8 lg of VSVG plasmid using Fugene6 (Roche) following the manufacturer's instructions. The resulting supernatant was collected 48 h after transfection, filtered through a 0.45 lm pore-size cellulose acetate filter (Whatman), and concentrated using Amicon ultra centrifugal filter units (Millipore) during 15 minutes at 3000 rpm and 4 C. After infection, cell medium was refreshed with human ES media (DMEM/F12 supplemented with 20% Knock-out serum and 10 ng/ml of bFGF). ES-like colonies were picked and then amplified for further characterization in feeder free condition.
Cell culture for human iPSC and ES cells
Human iPSC and ES (H9) cells were grown in feeder free conditions on Matrigel (BD Biosciences) in mTESR1 media (Stem Cells technologies) according to the manufacturer's instructions.
Neural differentiation
NPC differentiation of ESCs and iPSCs was done based on established protocols (52) . Cells were first plated in clumps on matrigel-coated 6 well-plates using mTESR1 media. The following day, the medium was changed with NPC media composed of DMEM-F12/Neurobasal media (1:1) supplemented with N2 and B27 without vitamin A supplements and CHIR99021 (4 mM), SB431245 (3 mM), CompoundE (0.1 mM) and human LIF (10 ng/ml). After 7 days, cells were passaged using accutase and grown in the same media using CHIR99021 (3 mM) and SB431245 (2 mM) together with LIF (10 ng/ml), EGF and bFGF (20 ng/ml).
For neuronal differentiation NPCs were plated at a density of 200,000 cells per 6 well and grown in DMEM-F12/Neurobasal media (1:1) supplemented with N2 and B27 supplements together with GDNF (20 ng/ml), BDNF (20 ng/ml), dibutyryl-cyclic AMP (1 mM) and Acid ascorbic (200 nM) for at least 4 weeks. For characterization, neurons were passaged using accutase and replated at very low density (5,000 cells per 24 well) on coverslips.
EdU cell cycle assay
Proliferation assay was quantified by using 5-ethynyl-2-deoxyuridine (EdU) incorporation kit, Click-iT EdUAlexa Fluor 647-Flow assay (Molecular Probes, Thermo Scientific). Briefly, EdU (15 mM) was added into NPCs for 2 h and incubated in 37 C, 5% CO 2 incubators. Cells were harvested after 2 h. Click-IT reaction was performed according to manufacturer's protocol. The percentages of EdU-incorporated cells were quantified by using BD FACS Aria Cell Sorter.
Immunocytochemistry
Cells were plated on ethanol treated coverslips and fixed with 4% paraformaldehyde in phosphate buffered saline (PBS) at 4C and incubated with Tris Buffer Saline (TBS) containing 5% of serum, 1% BSA (Bovine Serum Albumin, Sigma-Aldrich) and 0.1% of Triton X-100 (Sigma-Aldrich) for 45 minutes at room temperature. Primary antibodies were incubated with fixed cells overnight at 4 C, and cells were subsequently stained with secondary antibody conjugated to Alexa Fluor 594 or 488 (Molecular probes) (4 mg/ml) for 1 h at room temperature in the dark. Images were captured using a ZEISS AxioObservor DI inverted fluorescence microscope (Carl Zeiss International).
Microarray
Human Ref-12 Expression BeadChip microarrays (Illumina) were used for genome-wide expression analysis. For hybridization, cRNAs from duplicate or triplicate samples were synthesized and labelled using the TotalPrep RNA Amplification Kit (Ambion), following the manufacturer's instructions. Scanned data from the BeadChip raw files for all samples were retrieved and background corrected using BeadStudio, and subsequent analyses were completed in GeneSpring GX. Data were normalized both within and between arrays, and corrected for multiple testing according to Benjamini-Hochberg. We defined genes as significantly differentially expressed when the FDR is <0.05. Microarray data are available in the GEO database under the accession number GSE87568.
RNA interference
Pre-designed pLKO.1 vectors harbouring an shRNA sequence targeting GTDC1 were purchased from Sigma-Aldrich (www.sig maaldrich.com). The sequence of the duplexes is CCGGCCTGC TGCTTAAAGTCAGATTCTCGAGAATCTGACTTTAAGCAGCAGGT TTTG for shGTDC1 #1 and CCGGTGGGTCAGTAAGATGATTGATC TCGAGATCAA TCATCTTACTGACCCATTTTTG for shGTDC1 #3. Viral particles were produced using the pLKO.1 protocol available online and concentrated using Amicon ultra centrifugal filter units (Millipore) during 15 minutes at 3000rpm and 4C. For infection, NPCs derived from H1 human ES cells were seeded in 6-well plates at about 200.000 cells per well in NPC medium.
Following infection, the medium was replaced with fresh media.
Morpholino microinjection
Antisense morpholino (MO) for zebrafish glycosyltransferaselike domain containing-1 (NM_001017560.1) sequences were designed by the manufacturer to target the splice site between exon 5 and 6 (gtdc1 MO: ACGTTATCATGAGCGTCTCACCAGC), and complemented with control MO (control MO: AACTCCTCGGATTTTTTATGACGTC) (GeneTools). Subsequently, 8 ng of each MO was injected into the yolk of one to two cell stage embryos from wild type AB zebrafish strains. Injected embryos were incubated at 28.5 until reaching the appropriate developmental stage. Consistent phenotype was observed in at least three independent experiments of around 100 embryos each. The embryos were then fixed in 4% paraformaldehyde in PBS (PFA/PBS) overnight in 4 C and stored in the gradual increase of Methanol hydration in 100% MeOH at À20 C overnight. For the rescue experiment by co-injection of MO with human GTDC1 mRNA, we obtained full-length GTDC1 coding sequence (NM_001006636.3) in a pCMV-AC-GFP-backbone plasmid (Plasmid ID: RG221336, Origene). After digesting the plasmid with Xho1, capped mRNA was synthesized by T7 mMessage Machine kit (Ambion, Thermo Scientific) according to manufacturer's instruction. Capped mRNA was purified by using the RNAeasy mini kit (Qiagen) and approximately 200 pg of RNA was co-injected together with MOs for rescue experiments.
Zebrafish whole-mount in situ hybridization
Whole mount in situ hybridizations of zebrafish embryo (WISH) were carried out as previously described by Thisse et al. (62) . Briefly, embryos were rehydrated with PBS from concentrated MeOH, and digested with Proteinase K according to embryo stage. The embryos were then fixed in 4% PFA and washed several times with PBS, before pre-hybridization at 70 C in shaking water bath. Hybridization of 300 ng of antisense probe was performed overnight at 70 C. The next day, embryos were washed in salt-solutions (decreasing 2Â SSC concentration) at 70 C, and blocked for 1 h at room temperature in a blocking solution (5% Lamb serum, 2 mg/ml BSA, 1% Dymethyl Sulfoxide in 0.1% PBSTween). Anti-DIG Alkaline Phosphatase antibody at dilution 1:2000 (Roche) was added to the blocking solution and incubated overnight at 4 C. The next day, alkaline-phosphatase staining solution, NBT-BCIP, was added to the Alkaline-Tris buffer containing 100 mM Tris-HCl pH 9.5, 50 mM MgCl 2 , 100 mM NaCl and 0.1% Tween 20, and used for staining the washed embryo for 2-3 h at room temperature. Embryos were fixed in 4% PFA upon desirable staining intensities, and mounted on 50% glycerol:PBS for capturing images on Leica microscopes.
Quantification assays
To determine the proportion of positive cells in each sample, images were captured at 40Â magnification from at least 5-6 images. ImageJ software was used to compute the total number of cells (DAPI stained nuclei) and the number of cells expressing TuJ1, MAP2 or NESTIN. Soma size was measured by ImageJ from at least 60 soma per image using DAPI and TuJ1 stained neurons. For this, somas were outlined in ImageJ and surface area (¼ soma size) calculated. A minimum of 100 cells per line from two experiments were analysed and used to estimate the average soma size. Axon calibre was measured with ImageJ. Map2/ Tuj1-positive cells were outlined by drawing a line vertically to measure the thickness of neurites. Axon thickness was measured from at least 10 Map2-Tuj1-positive neurons from each sample. Neurite outgrowth was characterized by counting the number of neurite extensions per cell body, and counted at least 10 Tuj1-positive neurons per image. All data were expressed as the mean 6 standard error of the mean from three individual experiments. Neuronal maturation was measured by colocalization PlugIn in ImageJ based on the threshold quantification of overlapping signal between TUJ1 and MAP2-positive neurons. Statistical analysis was carried out using Kruskal-Wallis nonparametric test between the control and samples, and significance was defined with: * for p values between 0,05 and 0,01; ** for P-values between 0,01 and 0,001 and *** for P-values < 0,001.
